EXPERIENCE WITH ACERBIN® IN THE TREATMENT OF PROBLEM WOUNDS

The specific features of problem wounds are long-term healing, resistance to traditional treatment, and limited efficacy of used medications. The efficacy of Acerbin® solution is due to the clinical effect of its each component on the individual components of a wound process (activated necrolysis, reduced wound exudation, stimulated development of granulation tissue and epitheliazation).

Objective: to clinically test Acerbin® spray and to determine its medical efficacy.

 Materials and methods. Acerbin® was clinically tested in 39 patients with problem wounds at different sites: excessive pressure ulcers of the sacrum, greater trochanter, and ischial tuberosity in the presence of spinal injury (n = 12 (30.8 %)), sluggish granulating purulent wounds after phlegmon lancing or amputations in the presence of a diabetic foot (n = 6 (15.4 %)), neuropathic diabetic ulcers of the foot and leg (n = 7 (17.9 %)), venous trophic ulcers (n = 10 (25.6 %)), extensive skin and fascial defects after necrotizing fasciitis of the hip and abdominal wall in the presence of diabetes mellitus (n = 4 (10.3 %)).

Results. Acerbin® was shown to exert a positive effect on a wound process in treating problem wounds: necrolysis acceleration and wound cleansing from pyonecrotic tissues up to 5.2 ± 0.6 days versus 16.7 ± 0.9 days in the comparison group (p < 0.05); emergence of active granulations after 6.3 ± 0.4 days versus 17.2 ± 1.1 days in the comparison group (p < 0.05); wounds healed by secondary intention in the majority of patients (n = 23 (58.9 %)); conditions were created for wound plastic closure in 12 (30.7 %) cases.

Conclusion. The investigation has verified the high efficacy of Acerbin® and the possibility of its wide application to wounds as a whole and expansion of indications for the therapy for problem wounds.

1. Mathieu D., Linke J.C., Wattel F. Non-healing wounds. In: Handbook on hyperbaric medicine. Netherlands: Springer, 2006. Pp. 401–27.

2. Menke N.B., Ward K.R., Witten T.M. et al. Impaired wound healing. Clin Dermatol 2007;25(1):19–25.

3. Smith A.S. Etiology of the problem wound. In: Sheffield P.J., Fife C.E. Wound care practice. 2nd edn. Flagstaff: Best Publishing Company, 2007. Pp. 5–50.

4. Jannasch O., Tautenhahn J., Dalicho S., Lippert H. The difficult wound. Ther Umsch 2007;64(suppl 9):485–94.

5. Edlich R.F., Winters K.L., Britt L.D. et al. Difficult wounds: an update. J Long Term Eff Med Implants 2005;15(3):289–302.

6. Onesti M.G., Fioramonti P., Carella S., Maruccia M. The importance of periwound skin in the treatment of difficult wound. G Chir 2011;32(1–2):83–8.

7. Eaglstein W.H., Falanga V. Chronic wounds. Surg Clin North Am 1997;77(3):689–700.

8. Harding K.G., Morris H.L., Patel G.K. Science, medicine and the future: healing chronic wounds. BMJ 2002;324(7330):160–3.

9. Stremitzer S., Wild T., Hoelzenbein T. How precise is the evaluation of chronic wounds by healthcare professionals? Int Wound J 2007;4(suppl 2):156–61.

10. Vowden P. Hard-to-heal wounds made easy. Wounds Int 2011;2(4):15–8.

11. Hard-to-heal wounds: a holistic approach. European Wound Management Association (EWMA) position document. London: MEP Ltd, 2008. Pp. 3–5.

12. Falanga V., Brem H., Ennis W.J. et al. Maintenance debridement in the treatment of difficult-to-heal chronic wounds. Recommendations of an expert panel. Ostomy Wound Manage 2008;Suppl:S2–13.

13. Панош Б. Мнение эксперта о препарате «Ацербин» производства компании «Монтавит», Австрия. МедиАль 2012;(1):62–3. [Panosh B. Expert opinion on Acerbine substance, manufactured by Montavit, Austria. МеdiAl’ 2012;(1):62–3. (In Russ.)].

14. Salicylic acid – a plant hormone. Ed. by S. Hayat, A. Ahmad. Berlin, 2007. P. 400.

15. Lloyd D.A., Mickel R.E., Kritzinger N.A. Topical treatment of burns using Aserbine. Burns 1989;15(2):125–8. 1

16. Алексеев А.А., Бобровников А.Э., Чечулина В.Е., Тусинова С.А. Опыт использования препарата «Ацербин» в комплексном местном лечении ожоговых ран. Комбустиология 2003;(14):1–3. [Alekseev А.А., Bobrovnikov А.E., Chechulina V.Е., Тusinovа S.А. Experience of use of Acerbine substance in the comprehensive local treatment of burn wounds. Kombustiologiya = Combustiology 2003;(14):1–3. (In Russ.)].

17. Богданец Л.И., Березина С.С., Кириенко А.И. Ацербин в лечении острого индуративного целлюлита у пациентов с трофическими язвами венозного генеза. Ангиология и сосудистая хирургия 2007;13(4):93–6. [Bogdanets L.I., Berezinа S.S., Kirienkо А.I. Аcerbine in the treatment of the acute indurative cellulites at patients with trophic ulcers of the venous genesis. Angiologiya i sosudistaya khirurgiya = Аngiology and Vascular Surgery 2007;13(4):93–6. (In Russ.)].

18. Богданец Л.И., Кириенко А.И., Журавлева О.В. Ацербин – новые возможности в лечении трофических язв венозного генеза. Русский медицинский журнал 2004;12(24):10–3. [Bogdanets L.I., Kirienkо А.I., Zhuravlevа О.V. Аcerbine – new opportuniries in the treatment of trophic ulcers of the venous genesis. Russkiy meditsinskiy zhurnal = Russian Medical Journal 2004;12(24):10–3. (In Russ.)].

19. Звягинцева Т.В., Халин И.В. Метаболитотропная терапия хронических ран. Харьков, 2011. 183 с. [Zvyagintsevа Т.V., Khalin I.V. Меtabolitic tropic therapy of chronic wounds. Khar’kov, 2011. 183 p. (In Russ.)].

20. Патент RU 2454187 C1. Способ раневого диализа гнойных ран при сахарном диабете. А.В. Блескина, Ю.С. Винник, В.Л. Фаттахов и др. 27.06.2012. Бюл. № 18. [Patent RU 2454187 C1. Method of wound dialysis of septic wounds at diabetes mellitus. А.V. Bleskinа, Yu.S. Vinnik, V.L. Fattakhov et al. 27.06.2012. Bul. No 18. (In Russ.)].

21. Янченко А.А., Плотникова Е.А. Применение препарата Ацербин в хирургической практике. Новосибирск, 2008. С. 10–3. [Yanchenkо А.А., Plotnikovа Е.А. Application of Acerbine substance in surgical practice. Novosibirsk, 2008. Pp. 10–3. (In Russ.)].